Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-to-present-positive-long-term-results-of-kp104-in-phase-2-paroxysmal-nocturnal-hemoglobinuria-pnh-study-at-the-2024-european-hematology-association-eha-hybrid-congress-302147046.html
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-presents-positive-results-of-kp104-phase-2-study-in-complement-naive-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-at-the-2023-ash-annual-meeting-302015683.html
https://www.clinicaltrialsarena.com/news/kira-bifunctional-biologic-trial/
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-announces-first-cohort-of-patients-dosed-in-phase-2-study-of-kp104-in-paroxysmal-nocturnal-hemoglobinuria-pnh-301689797.html
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-to-present-first-in-human-clinical-data-at-american-society-for-nephrology-kidney-week-2022-301650417.html
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-to-participate-in-upcoming-investor-conferences-301648070.html
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-to-present-new-preclinical-data-on-lead-asset-kp104-at-the-2022-european-meeting-on-complement-in-human-disease-conference-301612895.html
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-receives-fda-orphan-drug-designation-for-kp104-a-bifunctional-antibody-fusion-protein-for-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria-301594815.html
https://www.prnewswire.com/news-releases/kira-pharmaceuticals-appoints-teri-loxam-as-chief-operating-officer-and-chief-financial-officer-301424613.html